Pharmaceuticals, Biotechnology and Life Sciences
SBTI ID
40009857
Localisation
Japan
Asia
Secteur d'activité
Pharmaceuticals, Biotechnology and Life Sciences
Type d'organisation
Corporate
Dernière mise à jour
17/10/2019
Statut
Classification
2°C
Année cible
2030
Japanese pharmaceutical company Taiho Pharmaceutical commits to reduce absolute scope 1 and 2 GHG emissions 30% by 2030 from a 2017 base year. Taiho Pharmaceutical also commits to reduce absolute scope 3 GHG emissions 20% by 2030 from a 2017 base year.
The targets covering greenhouse gas emissions from company operations (scopes 1 and 2) are consistent with reductions required to keep warming to 2°C
Source : Science Based Targets initiative | Données publiques